Since 1997 rabbit haemorrhagic disease virus (RHDV) has been used in New Zealand as a biological control agent to reduce pest rabbit populations but the effectiveness of RHDV is waning. One contributing factor is the increasing number of rabbits acquiring immunity to RHDV early in life. In other countries, RHDV immunity is influenced by the presence of benign rabbit caliciviruses (RCVs) which can confer a degree of cross protection against the pathogenic RHDV. Antibodies that reacted against RHDV were found in wild rabbits sampled before 1997, suggesting benign RCVs were present in New Zealand prior to the arrival of RHDV. Early attempts to isolate NZ RCV failed. In the present study serological and molecular tools were used to screen for caliciviruses in samples from over 400 wild New Zealand rabbits. A specific RCV blocking ELISA [1] was used to study the RCV antibody prevalence across different geographical regions. Antibody profiles indicate that RCV infection is acquired early in life. A universal lagovirus PCR test [2] identified a novel RCV strain from the duodenum of healthy wild rabbits. Sequencing and phylogenetic analysis of the capsid region revealed the virus shares a most recent common ancestor with Australian RCV strains but, with 88% nucleotide similarity, is distinctly different. The characteristics of NZ RCV were examined in laboratory rabbits (n=18) by measuring tissue viral loads and virus shedding for up to 28 days post infection. Results indicate the virus is non-pathogenic. Prior to the discovery of the NZ RCV strain, 10 wild rabbits with pre-existing RCV antibodies were challenged with RHDV. Results suggest the NZ RCV strain may provide a degree of cross-protection against RHDV but this needs to be confirmed in more comprehensive studies. The knowledge gained from this study will assist understanding virus-host/virus-virus interactions and ultimately aid future rabbit biocontrol efforts.